

Asthma Committee meeting

Date: 14/07/2022

Location: Virtual meeting

Minutes: Final

Committee members present:		
Lynn Elsey		Present for notes 1-5
Matthew Doyle		Present for notes 1-5
Kevin Gruffydd-Jones		Present for notes 1-5
Stephen Fowler (Topic Adviser)		Present for notes 1-5
Alan MacDonald (Co-Chair)		Present for notes 1-5
Kenneth Macleod		Present for notes 1-5
Andrew Molyneux (Co-Chair)		Present for notes 1-5
Elia Monterio		Present for notes 1-5
Kay Roy		Present for notes 1-5
Ian Sinha (Topic Adviser)		Present for notes 1-5
Edwina Wooler		Present for notes 1-5

In attendance:		
Lola Adewale	SIGN Programme Manager	Present for notes 1-5
Stephen Deed	Information Specialist	Present for notes 1-5
Amber Hernaman	Project Manager	Present for notes 1-5
Bernard Higgins	Guideline Lead	Present for notes 1-5
Alfredo Mariani	Technical Analyst (Economics)	Present for notes 1-5
Toby Sands	Systematic reviewer	Present for notes 1-5
Nick Staples	Guideline Commissioning Manager	Present for notes 1-5

Melina Vasileou	Senior Systematic Reviewer	Present for notes 1-5
-----------------	-------------------------------	-----------------------

Apologies:

Amy Crisp

Natalie Harper

Sheba Joseph

Colin Wilkinson

1. Welcome and objectives for the meeting

The Co-Chair welcomed the Committee members and attendees to the sixth Asthma guideline committee meeting.

The Co-Chair informed the Committee that apologies had been received, these are noted above.

The Co-Chair outlined the objectives of the meeting, which included: drug classes for initial management and FeNO testing.

2. Confirmation of matter under discussion, and declarations of interest

The Co-Chair confirmed that, for the purpose of managing conflicts of interest, the matters under discussion were drug classes for initial management and FeNO testing.

The Co-Chair asked everyone to verbally declare any interests that have arisen since the last meeting. There were no new declarations of interest.

3. CDEs

TS and Ama presented the following CDE's for committee discussion:

- 3.1 Drug classes for initial management
- 4.1 Smart inhalers

The committee discussed the CDE's and made edits.

4. Evidence reviews

TS and AMa presented the following evidence review to the committee:

- 1.6 FeNO testing

The committee discussed the evidence presented and made draft recommendations.

5. Protocol

BH discussed protocol 2.4 on risk factors with the committee in order to agree the appropriate format of the question.

Any other business

None.

Date of next meeting: 14/09/2022

Location of next meeting: Virtual meeting